Navigation Links
Steve Jobs' Death Highlights Critical Need for New Therapies for Pancreatic Cancer
Date:10/10/2011

WHITE PLAINS, N.Y., Oct. 10, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) joins in grieving the untimely death of Apple Co-Founder Steve Jobs from pancreatic cancer. Jobs' death comes on the heels of other high profile deaths from the disease - those of Nobel Laureate Ralph Steinman last week, and actor Patrick Swayze two years ago.

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

These deaths bring to light a disease with an extremely poor prognosis for which there are limited therapies. The five-year relative survival rate for this patient population is less than five percent.

But better news may come in the form of therapies originally approved to treat patients with blood cancers. Roughly 50 percent of the cancer drugs approved by the Food & Drug Administration (FDA) in the past decade were first approved to treat patients with a form of blood cancer. Many of these drugs are now commonly used to help additional patients and some are showing promise against certain solid tumors, including pancreatic cancer.

LLS helped advance Revlimid®, a drug that can enhance anti-cancer immune responses and block cancer-feeding blood supplies. It is FDA-approved for patients diagnosed with myeloma or myelodysplastic syndromes.  Based on exciting laboratory results, Revlimid is now being tested with a standard chemotherapy in clinical trials for pancreatic cancer patients.

Likewise, LLS funded research advanced Zolinza®, a first-in-class enzyme-targeting drug that can kill cancer cells by reprogramming critical gene activities. Zolinza is FDA-approved to treat certain lymphoma patients, and being tested in clinical trials for pancreatic cancer patients.

"The passing of the visionary Steve Jobs was a truly sad occasion and his death has brought attention to a deadly cancer for which there are very limited options for patients," said LLS President and CEO John Walter. "But as with many other diseases, therapies originally developed to treat patients with blood cancer are showing real promise and we are hopeful that these advances will one day soon help patients with pancreatic cancer."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

Andrea Greif
(914)821-8958
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stevens researchers pioneer novel technique to make plasmonic nanogap arrays
2. ONR funds study of nanoscale wetting dynamics of superhydrophobic surfaces at Stevens
3. Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way"
4. Dr. Frank Fisher of Stevens selected for Fulbright specialist roster
5. Steven Seagal Asks For Russian PM Vladimir Putins Support in Immortality Research
6. Dr. Stefan Strauf of physics at Stevens receives NSF CAREER Award for quantum research
7. Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011
8. Nanoimprint lithography NSF grant awarded to micro device lab at Stevens
9. Microfluidic devices advance 3-D tissue engineering at Stevens
10. Xiaoguang Meng receives honorary master of engineering from Stevens
11. AMTs EGM Passes All Resolutions and Strengthens Supervisory Board With Joseph Feczko, Steven Holtzman and Francois Meyer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016  Genprex, Inc. a ... immunogene therapy treatments, today announced that it has ... a leading strategic communications and advisory firm, to ... The program will combine investor relations, public relations ... raising the profile of Genprex and its lead ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... today a new service to enable rapid migration of large pathology data sets ... one of the factors limiting adoption of digital pathology. Proscia’s free massive dataset ...
(Date:12/6/2016)... Dec. 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... the fourth quarter and fiscal year ended September 30, 2016. ... , , ... life sciences and diagnostics company that develops and commercializes proprietary technologies ... Achieved revenues of $1.4 million more than tripling ...
(Date:12/6/2016)... ... December 06, 2016 , ... Symbios Technologies, Inc. , ... company has engaged in a collaborative research partnership with Colorado State University (CSU) ... of the Vice President for Research. This agreement is designed to further the ...
Breaking Biology Technology:
(Date:11/24/2016)... 23, 2016 Cercacor today introduced Ember TM ... trainers non-invasively measure hemoglobin, Oxygen Content, Oxygen ... Respiration Rate in approximately 30 seconds. Smaller than a ... immediate access to key data about their bodies to ... regimen. Hemoglobin carries oxygen to muscles. ...
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
Breaking Biology News(10 mins):